acetazolamide has been researched along with Friedreich Ataxia in 2 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Friedreich Ataxia: An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The acetazolamide trial was terminated at 7 to 11 weeks because of reported side effects or increased ataxia in 3 of the patients." | 1.27 | Quantitative evaluation of the effects of acetazolamide in Friedreich's ataxia: a pilot study. ( Bouchard, JP; Dumas, F; Richards, CL; Tardif, D, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richards, CL | 1 |
| Bouchard, JP | 1 |
| Dumas, F | 1 |
| Tardif, D | 1 |
| Griggs, RC | 1 |
| Moxley, RT | 1 |
| Lafrance, RA | 1 |
| McQuillen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for acetazolamide and Friedreich Ataxia
| Article | Year |
|---|---|
Hereditary paroxysmal ataxia: response to acetazolamide.
Topics: Acetazolamide; Adolescent; Adult; Aged; Child, Preschool; Clinical Trials as Topic; Female; Friedrei | 1978 |
1 other study available for acetazolamide and Friedreich Ataxia
| Article | Year |
|---|---|
Quantitative evaluation of the effects of acetazolamide in Friedreich's ataxia: a pilot study.
Topics: Acetazolamide; Adolescent; Child; Drug Evaluation; Electromyography; Female; Friedreich Ataxia; Gait | 1984 |